New option for adults with IPF and PPF

SEGRAM aims to offer an alternative to glucocorticoid‑based treatment

Second phase 3 trial shows sustained benefit and supports forthcoming regulatory submission

New phase 3 trial to assess impact on disease progression, function and quality of life

Option offers once‑daily semaglutide tablets for adults living with obesity

Deal brings together Novartis oncology capabilities with Myricx Bio’s next‑gen ADC platform

Accelerator seeks early‑stage data‑driven health ventures for five‑month programme

EC backs first gene replacement therapy for broad sma population

QuantumCell gains global rights to NeuroRestore platform in deal worth over USD 2.2 billion

Experts join new group as therapy moves into phase 2b